Chronic Obstructive Pulmonary Disease (COPD) - Complete Guide

1. Definition

• Chronic bronchitis is defined clinically: persistent productive cough for at least 3 consecutive months in at least 2 consecutive years
• Emphysema is defined anatomically: permanent enlargement and destruction of airspaces distal to the terminal bronchioles

2. Epidemiology & Risk Factors

• Third most common cause of death in the United States
• Costs over $40 billion/year in direct and indirect healthcare costs
• Only 10-15% of smokers develop clinically significant disease (genetic susceptibility matters)
• Heritability of COPD is estimated at 37-50%
• COPD usually develops ~10-12 years after smoking initiation

Any patient developing COPD before age 45 or without significant smoking history should be screened for A1AT deficiency

3. Pathophysiology

3a. Core Mechanism - Protease-Antiprotease Imbalance

1. Noxious stimuli (cigarette smoke, pollutants) → recruitment of neutrophils, macrophages, and CD8+ lymphocytes to the lung
2. These inflammatory cells release proteases (elastase, matrix metalloproteinases)
3. Proteases destroy the elastic support structures of alveolar walls
4. Normally, alpha-1 antitrypsin (A1AT) inhibits neutrophil elastase - when this fails, destruction proceeds unchecked
5. Oxidative stress from reactive oxygen species amplifies the inflammatory cascade

3b. Emphysema Pathway

Cigarette smoke → Alveolar macrophage + Neutrophil activation
         ↓
   Protease release (elastase, MMPs)
         ↓
   Alveolar wall destruction + Loss of elastic recoil
         ↓
   Enlarged air spaces + Air trapping (static hyperinflation)
         ↓
   Loss of radial tethering → Dynamic airway collapse on expiration
         ↓
   Dynamic hyperinflation → Barrel chest

• Cigarette smoking also causes intimal thickening and smooth muscle proliferation in pulmonary vasculature, with decreased VEGF expression and endothelial cell apoptosis, contributing to pulmonary hypertension

3c. Chronic Bronchitis Pathway

Tobacco smoke / pollutants → Mucosal irritation
         ↓
   Goblet cell metaplasia + Mucous gland hypertrophy (Reid index >0.4)
         ↓
   MUC5AC concentration ↑ 10-fold; MUC5B ↑ 3-fold
         ↓
   Mucus hypersecretion + Ciliary dysfunction (CFTR ↓, ENaC ↑)
         ↓
   Persistent airway infection (especially H. influenzae)
         ↓
   Small airway inflammation → Bronchiolitis → Fibrosis
         ↓
   Airflow obstruction (primary site = small airways <2 mm)

3d. Emphysema Subtypes

3e. Pulmonary Function Consequences

• Increased residual volume (RV) and functional residual capacity (FRC) due to air trapping
• Decreased FEV1 due to loss of elastic recoil and airflow obstruction
• FEV1/FVC ratio < 0.70 (hallmark of obstructive defect)
• V/Q mismatch → hypoxemia
• Dynamic hyperinflation → diaphragm flattening, barrel chest, increased work of breathing
• In emphysema: hypoxemia alone (compensated by hyperventilation)
• In chronic bronchitis: both hypoxemia and hypercapnia (CO2 retention)

4. Genetics - Alpha-1 Antitrypsin Deficiency

• Most common monogenic risk factor for COPD
• Encoded by the SERPINA1 gene - product is a serine protease inhibitor synthesized and secreted by the liver
• Alleles designated by electrophoretic mobility: M (normal), S (slow), Z (ultraslow)
• Normal genotype: PiMM (present in ~95% of adults)
• Pathologic genotypes: PiZZ (most severe - very low A1AT), PiSS, PiZS
• PiZZ homozygotes have markedly elevated risk of emphysema (panacinar, lower lobe)
• Even PiMZ heterozygotes show more airflow impairment and CT emphysema than PiMM

5. Clinical Features

Classic Presentation

• Onset in midlife (typically after age 40), with slow progression over decades
• Progressive dyspnea - initially only on exertion, later at rest
• Chronic productive cough (morning sputum common)
• Long history of cigarette smoking

Emphysema "Pink Puffer" vs. Chronic Bronchitis "Blue Bloater"

Physical Examination Signs

• Barrel chest (increased AP diameter) - due to chronic hyperinflation
• Flattened diaphragm on chest X-ray and percussion
• Prolonged expiratory phase with expiratory wheeze
• Decreased breath sounds globally
• Use of accessory muscles of respiration
• Pursed-lip breathing (to maintain positive expiratory pressure)
• In severe disease: peripheral edema, cyanosis, cor pulmonale

Chest X-Ray Findings (COPD)

6. Diagnosis

Key Diagnostic Test: Spirometry

• COPD is diagnosed by post-bronchodilator FEV1/FVC < 0.70
• Unlike asthma, airflow limitation in COPD is not fully reversible (< 12% improvement with bronchodilator)
• Patients with normal spirometry but symptoms + CT emphysema are NOT classified as COPD

• ↓ FEV1
• ↓ FEV1/FVC ratio (< 0.70)
• ↑ RV and TLC (air trapping)
• ↓ DLCO (in emphysema - destruction of gas exchange surface)
• Normal or near-normal FVC

GOLD Classification (Severity by FEV1 post-bronchodilator, with FEV1/FVC < 0.70)

GOLD ABCD Assessment Tool (Beyond Spirometry)

• Symptom burden: assessed by mMRC (≥2 = more symptomatic) or CAT score (≥10 = high symptoms)
• Exacerbation history: ≥2 moderate exacerbations/year, or ≥1 requiring hospitalization = high risk

Other Investigations

• ABG: hypoxemia (PaO2 < 60 mmHg), possible hypercapnia (PaCO2 > 45 mmHg), A-a gradient elevated
• CXR: hyperinflation, flat diaphragms, bullae, increased AP diameter
• HRCT chest: best for identifying emphysema pattern, extent; also detects bronchiectasis
• ECG: right ventricular strain pattern (P pulmonale, right axis deviation) in cor pulmonale; arrhythmias in up to 35%
• A1AT level: screen if young onset or no smoking history
• CBC: polycythemia (secondary, due to chronic hypoxia)
• 6-minute walk test: distance < 149 m = severe functional limitation

7. Complications

1. Cor pulmonale (right heart failure): from chronic hypoxia → pulmonary vasoconstriction → pulmonary hypertension → right ventricular hypertrophy and failure
2. Pulmonary hypertension
3. Acute exacerbations (major driver of morbidity and mortality)
4. Recurrent respiratory tract infections (H. influenzae, S. pneumoniae, M. catarrhalis; viral most common)
5. Respiratory failure (hypoxic and/or hypercapnic)
6. Pneumothorax (especially with bullous disease/paraseptal emphysema)
7. Secondary polycythemia (compensatory erythrocytosis)
8. Cardiovascular disease: increased risk of coronary artery disease, arrhythmias, heart failure (major comorbidity)
9. Lung cancer: significantly elevated risk
10. Malnutrition, cachexia, and muscle wasting
11. Obstructive sleep apnea (overlap syndrome)
12. Depression and anxiety (very common, often undertreated)

8. Management

8a. Non-Pharmacological (All Patients)

8b. Pharmacological - Stable COPD

Key note on ICS: Recommended ONLY for severe airflow obstruction, frequent exacerbations, or blood eosinophils ≥ 100-300/µL. Avoid in patients with low eosinophils due to higher bacterial pneumonia risk and limited benefit. Blood eosinophil count now guides ICS decision-making in COPD.

Theophylline: A recent large placebo-controlled RCT found low-dose theophylline did NOT reduce exacerbation frequency - no longer recommended.

8c. Surgical Options (Severe COPD)

• Lung volume reduction surgery (LVRS): for upper-lobe predominant emphysema with poor exercise capacity; improves survival in selected patients
• Bullectomy: for giant bullae compressing normal lung tissue
• Lung transplantation: for end-stage COPD (GOLD 4), especially A1AT deficiency-related
• Bronchoscopic lung volume reduction: endobronchial valves (Zephyr) as less invasive alternative

9. Acute Exacerbation of COPD (AECOPD)

Triggers

• Viral respiratory infections (most common - ~50-70%)
• Bacterial infections (30-50%): H. influenzae, S. pneumoniae, M. catarrhalis (Pseudomonas in severe/bronchiectatic disease)
• Environmental pollutants, particulate matter
• Temperature changes, pulmonary embolism

Severity Assessment - Indications for Hospitalization

• Severe dyspnea not responding to initial therapy
• Change in mental status (confusion, lethargy)
• PaO2 < 40 mmHg or SaO2 < 90%
• PaCO2 > 60 mmHg or pH ≤ 7.25
• Hemodynamic instability
• Failure of outpatient treatment
• Significant comorbidities (CHF, arrhythmias, electrolyte imbalance)

Treatment of AECOPD

• SABA ± SAMA via nebulizer or MDI with spacer
• Combining ipratropium + albuterol is more effective than either alone

• Oral prednisone 40 mg for 5 days (5-day = as effective as longer courses)
• Decrease recovery time, improve oxygenation, improve lung function, decrease hospital stay
• IV methylprednisolone if patient cannot take oral

• Indicated if: increased sputum purulence PLUS increased dyspnea OR increased sputum volume (Anthonisen criteria)
• First-line: amoxicillin/clavulanate, macrolides (azithromycin), or tetracyclines (doxycycline)
• Coverage for Pseudomonas if: severe airflow limitation, known bronchiectasis, or requiring mechanical ventilation
• Duration: 5 days macrolides; 7 days amoxicillin/clavulanate or tetracyclines

• Target SpO2: 88-92% (not higher - avoids hypercapnia from altered V/Q and loss of hypoxic vasoconstriction)
• Titrate carefully - both hypoxemia AND hyperoxemia are harmful

• Indicated for: moderate to severe respiratory failure with pH < 7.35 and PaCO2 > 45
• Reduces risk of intubation by 65%, in-hospital mortality by 55%, hospital stay by 1.9 days
• Requires: normal mental status, hemodynamic stability, no high aspiration risk
• ~80% of appropriate patients improve within 4 hours

• For patients who fail NIV or have contraindications
• Worsening mental status, respiratory arrest, hemodynamic instability

• DVT prophylaxis (subcutaneous heparin)
• Cardiac monitoring (arrhythmias in up to 35% of exacerbations)
• Electrolyte monitoring and correction
• Vitamin D supplementation if deficient (< 25 nmol/L)
• Smoking cessation counseling
• Ensure up-to-date vaccinations

10. Differential Diagnosis of COPD

11. Summary Table - "Pink Puffer vs Blue Bloater" Physiology (from Costanzo Physiology)

12. Recent Evidence (2024-2026)

• AECOPD risk prediction (2024) - A 2024 systematic review/meta-analysis in Respiratory Research analyzed prognostic risk prediction models for acute exacerbations (PMID: 39543648)
• Digital health for COPD (2025) - A 2025 meta-analysis in J Med Internet Res found digital health interventions improve COPD outcomes (PMID: 40418567)

• Robbins & Kumar Basic Pathology (Robbins Pathology)
• Fishman's Pulmonary Diseases and Disorders, 2-Volume Set
• Katzung's Basic and Clinical Pharmacology, 16th Edition
• Goldman-Cecil Medicine
• Murray & Nadel's Textbook of Respiratory Medicine
• Rosen's Emergency Medicine: Concepts and Clinical Practice
• Costanzo Physiology, 7th Edition
• Textbook of Family Medicine, 9th Edition